These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease. Kolho KL; Valtonen E; Rintamäki H; Savilahti E Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351 [TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140 [TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Persson M; Engström G; Björkbacka H; Hedblad B Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776 [TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410 [TBL] [Abstract][Full Text] [Related]
16. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388 [TBL] [Abstract][Full Text] [Related]
17. The role of tissue factor in patients undergoing open repair of ruptured and nonruptured abdominal aortic aneurysms. Hobbs SD; Haggart P; Fegan C; Bradbury AW; Adam DJ J Vasc Surg; 2007 Oct; 46(4):682-6. PubMed ID: 17764874 [TBL] [Abstract][Full Text] [Related]
18. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Pawlak K; Pawlak D; Mysliwiec M Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495 [TBL] [Abstract][Full Text] [Related]